ATE490954T1 - Estergebundene geminitensidverbindungen zur verwendung in der gentherapie - Google Patents

Estergebundene geminitensidverbindungen zur verwendung in der gentherapie

Info

Publication number
ATE490954T1
ATE490954T1 AT06701592T AT06701592T ATE490954T1 AT E490954 T1 ATE490954 T1 AT E490954T1 AT 06701592 T AT06701592 T AT 06701592T AT 06701592 T AT06701592 T AT 06701592T AT E490954 T1 ATE490954 T1 AT E490954T1
Authority
AT
Austria
Prior art keywords
ester
gemini surfactant
surfactant compounds
gene therapy
linked
Prior art date
Application number
AT06701592T
Other languages
English (en)
Inventor
Mariano Javier Castro
Christopher Kitson
Mark Ladlow
Alpesh Patel
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE490954T1 publication Critical patent/ATE490954T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT06701592T 2005-02-07 2006-02-03 Estergebundene geminitensidverbindungen zur verwendung in der gentherapie ATE490954T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0502482.3A GB0502482D0 (en) 2005-02-07 2005-02-07 Novel compounds
PCT/EP2006/000998 WO2006082088A1 (en) 2005-02-07 2006-02-03 Ester-linked gemini surfactant compounds for use in gene therapy

Publications (1)

Publication Number Publication Date
ATE490954T1 true ATE490954T1 (de) 2010-12-15

Family

ID=34355904

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06701592T ATE490954T1 (de) 2005-02-07 2006-02-03 Estergebundene geminitensidverbindungen zur verwendung in der gentherapie

Country Status (8)

Country Link
US (2) US7425645B2 (de)
EP (1) EP1848684B1 (de)
JP (1) JP4991567B2 (de)
AT (1) ATE490954T1 (de)
DE (1) DE602006018709D1 (de)
ES (1) ES2357140T3 (de)
GB (1) GB0502482D0 (de)
WO (1) WO2006082088A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138380A2 (en) 2005-06-15 2006-12-28 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
CA3144493A1 (en) * 2006-10-03 2008-04-10 Arbutus Biopharma Corporation Lipid containing formulations
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
SI2506857T1 (en) 2009-12-01 2018-08-31 Translate Bio, Inc. Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases
US9193827B2 (en) 2010-08-26 2015-11-24 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
ES2702428T3 (es) * 2010-11-15 2019-02-28 Life Technologies Corp Reactivos de transfección que contienen amina y métodos para prepararlos y usarlos
US8546338B2 (en) 2010-12-08 2013-10-01 Johnson & Johnson Consumer Companies, Inc. Self-assembling hydrogels based on dicephalic peptide amphiphiles
CA2831392C (en) 2011-03-28 2020-04-28 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
KR20220025112A (ko) 2011-06-08 2022-03-03 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
US9512073B2 (en) 2011-10-27 2016-12-06 Massachusetts Institute Of Technology Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof
EP3536787A1 (de) 2012-06-08 2019-09-11 Translate Bio, Inc. Nukleaseresistente polynukleotide und verwendungen davon
WO2014028487A1 (en) 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
KR102311614B1 (ko) 2013-03-14 2021-10-08 샤이어 휴먼 지네틱 테라피즈 인크. Cftr mrna 조성물 및 관련 방법 및 사용
EA201591229A1 (ru) 2013-03-14 2016-01-29 Шир Хьюман Дженетик Терапис, Инк. Способы очистки матричной рнк
US9315472B2 (en) 2013-05-01 2016-04-19 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
ES2707966T3 (es) 2013-10-22 2019-04-08 Translate Bio Inc Terapia de ARNm para la deficiencia en síntesis de argininosuccinato
EP3574923A1 (de) 2013-10-22 2019-12-04 Translate Bio, Inc. Mrna-therapie für phenylketonurie
ES3032935T3 (en) 2013-10-22 2025-07-29 Translate Bio Inc Lipid formulations for delivery of messenger rna
EP4729528A3 (de) 2014-04-25 2026-06-24 Translate Bio, Inc. Verfahren zur reinigung von messenger-rna
WO2015184256A2 (en) 2014-05-30 2015-12-03 Shire Human Genetic Therapies, Inc. Biodegradable lipids for delivery of nucleic acids
KR102559979B1 (ko) 2014-06-24 2023-07-25 샤이어 휴먼 지네틱 테라피즈 인크. 핵산의 전달용 입체화학적으로 풍부한 조성물
WO2016004202A1 (en) 2014-07-02 2016-01-07 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
RS64331B1 (sr) 2015-06-19 2023-08-31 Massachusetts Inst Technology Alkenil supstituisani 2,5-piperazindioni i njihova primena u sastavima za isporuku agensa u organizam ili ćeliju subjekta
MX2019010155A (es) 2017-02-27 2020-12-10 Translate Bio Inc Arnm de cftr optimizado por codón novedoso.
IL270631B2 (en) 2017-05-16 2024-03-01 Translate Bio Inc Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
US11174500B2 (en) 2018-08-24 2021-11-16 Translate Bio, Inc. Methods for purification of messenger RNA
AU2019384557B2 (en) 2018-11-21 2025-07-17 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR
CA3155003A1 (en) 2019-09-20 2021-03-25 Translate Bio, Inc. Mrna encoding engineered cftr

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565290A (en) * 1991-07-30 1996-10-15 Fuji Photo Film Co., Ltd. Desensitizing solution for offset printing
JPH05104878A (ja) * 1991-10-17 1993-04-27 Fuji Photo Film Co Ltd オフセツト印刷用不感脂化処理液
DE69420044T2 (de) 1993-10-29 2000-03-23 Smithkline Beecham Corp., King Of Prussia Blutregulierende peptide
JP3878208B2 (ja) * 1994-04-08 2007-02-07 ブラッコ インターナショナル ベスローテン フェンノートシャップ 芳香族アミド化合物およびそれらのキレート
WO1998008496A1 (en) * 1996-08-27 1998-03-05 The University Of Akron Lipophilic polyamine esters for the site specific delivery of nitric oxide in pharmaceutical use
GB9914045D0 (en) * 1999-06-16 1999-08-18 Smithkline Beecham Plc Novel compounds
EP1261620A2 (de) * 2000-02-07 2002-12-04 Roche Diagnostics Corporation Kationische amphiphile zur verwendung bei der nucleinsäuretransfektin
WO2004087656A1 (de) 2003-04-03 2004-10-14 Schering Aktiengesellschaft Konjugate 2,4-ethano- und 2,4-propano-überbrückter 3,6,9-triaza-nonansäure-3n, 6n, 9,9n-tetraessigsäure- und entsprechender phosphorsäuremethylen-derivate und deren abkömmlinge mit biomolekülen, verfahren zu deren herstellung und deren verwendung zur herstellung
GB0425556D0 (en) * 2004-11-19 2004-12-22 Glaxo Group Ltd Novel compounds
GB0425555D0 (en) * 2004-11-19 2004-12-22 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
US20080058279A1 (en) 2008-03-06
EP1848684A1 (de) 2007-10-31
US7569720B2 (en) 2009-08-04
WO2006082088A1 (en) 2006-08-10
DE602006018709D1 (de) 2011-01-20
GB0502482D0 (en) 2005-03-16
JP4991567B2 (ja) 2012-08-01
JP2009525259A (ja) 2009-07-09
US20080293829A1 (en) 2008-11-27
EP1848684B1 (de) 2010-12-08
ES2357140T3 (es) 2011-04-19
US7425645B2 (en) 2008-09-16

Similar Documents

Publication Publication Date Title
DE602006018709D1 (de) Estergebundene geminitensidverbindungen zur verwendung in der gentherapie
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
TW200604184A (en) Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
TN2012000142A1 (en) Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors
MX392756B (es) Pirimidinas modificadas en la posicion 5 y su uso
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
JO3134B1 (ar) مثبطات نشاط akt
ZA200701137B (en) Triazolophthalazines
MY159230A (en) P38 map kinase inhibitors
NZ607996A (en) Substituted nucleotide analogs
DE602005013775D1 (de) Verbesserte methode zur transformation von sojabohnen
SI1827441T1 (sl) Kombinacije za zdravljenje bolezni, povezanih s celično proliferacijo
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
CY1110860T1 (el) Αναστροφη μεταγραφαση τελομερασης πτηνου
MX2009014247A (es) Compuestos heterociclicos utiles como inhibidores de mk2.
WO2006072615A3 (en) Triazolophthalazines as pde2-inhibitors
MX2010001490A (es) Acidos nucleicos de enlace sdf-1 y uso de los mismos.
DK2089516T3 (da) Fremgangsmåder til at forbedre indføringen af DNA i bakterielle celler
MX2011001679A (es) Derivados de flavina.
WO2008043543A3 (de) Nucleic acid beacons for fluorescent in-situ hybridisation and chip technology
WO2006072612A3 (en) Triazolophthalazines as pde2- inhibitors
EP2116598A4 (de) Neuartige beta-galactosid-alpha-2,6-sialyltransferase, gen zu deren kodierung und verfahren zur erhöhung der enzymatischen aktivität
DE602007011324D1 (de) Verfahren zur herstellung von 2-substituierten 5-(1-alkylthio)alkylpyridinen
PL1924717T3 (pl) Sposoby zwiększania odwadnialności osadu ściekowego przez obróbkę alfa-amylazą
MX2009009916A (es) Tetrahidroquinolinas sustituidas.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties